Pharmaceutical composition with glycosaminoglycans and use thereof in the treatment of chronic ulcers

Abstract

The invention relates to a composition of glycosaminoglycans for the treatment of diabetic foot ulcer, it specifically relates to low molecular weight heparins (LMWHs) and very low molecular weight heparins (VLMWHs) in the treatment of chronic ulcers, particularly of diabetic foot ulcers, and more specifically in the manufacture of a medicinal product for the treatment of chronic ulcers, and particularly diabetic foot ulcers and pressure ulcers.

1 - 21 . (canceled) 
     
     
         22 . A pharmaceutical composition, comprising at least one low or very low molecular weight heparin,
 wherein a plasma half-life of the heparin is between 2.3 and 6.9 hours and an average daily dose of the heparin is between 5,400 and 10,000 IU/day, and   wherein the composition is suitable for treating a chronic ulcer.   
     
     
         23 . The pharmaceutical composition of  claim 22 , wherein the average daily dose is selected in an inversely proportional manner to the plasma half-life. 
     
     
         24 . The pharmaceutical composition of  claim 23  above wherein, when the plasma half-life of the heparin is between 6.5 and 6.9, the average daily dose is about 5,400 IU/day. 
     
     
         25 . The pharmaceutical composition of  claim 23  above wherein, when the plasma half-life of the heparin is between 4.0 and 4.4, the average daily dose is about 7,600 IU/day. 
     
     
         26 . The pharmaceutical composition of  claim 23  above wherein, when the plasma half-life of the heparin is about 3.0, the average daily dose is about 10,000 IU/day. 
     
     
         27 . The pharmaceutical composition of  claim 23  above wherein, when the plasma half-life of the heparin is between 2.3 and 2.8, the average daily dose is about 10,000 IU/day. 
     
     
         28 . The composition of  claim 22 , wherein the chronic ulcer is a diabetic foot ulcer. 
     
     
         29 . The composition of  claim 22 , wherein the chronic ulcer is a pressure ulcer. 
     
     
         30 . The composition of  claim 22 , wherein the low molecular weight heparin is present and is in a form for administering intravenously. 
     
     
         31 . The composition of  claim 22 , wherein the low molecular weight heparin is present and is in a form for administering subcutaneously. 
     
     
         32 . The composition of  claim 22 , wherein the low molecular weight heparin is present and is in a form for administering orally. 
     
     
         33 . The composition of  claim 22 , wherein the low molecular weight heparin is present and is in a form for administering topically. 
     
     
         34 . A method of manufacturing a medicinal product, the method comprising:
 combining the composition of  claim 22  with a carrier,   wherein the medicinal product is suitable for treating chronic ulcer.   
     
     
         35 . The method of  claim 34 , wherein the chronic ulcer is a diabetic foot ulcer. 
     
     
         36 . The method of  claim 34 , wherein the chronic ulcer is a pressure ulcer. 
     
     
         37 . A method of treating a chronic ulcer, comprising administering to a subject in need thereof, an effective amount of the composition of  claim 22 . 
     
     
         38 . The method of  claim 37 , wherein the chronic ulcer is a diabetic food ulcer. 
     
     
         39 . The method of  claim 37 , wherein the chronic ulcer is a pressure ulcer. 
     
     
         40 . The method of  claim 37 , wherein the administering is intravenous, subcutaneous, oral, or topical. 
     
     
         41 . The method of  claim 37 , wherein the administering is daily.